Veracyte | VCYT - 税前利润



金融业
股票价格
USD
资产
USD 1.49B
现金及等价物
USD 299.52M
销售成本
USD 42.19M
流动资产
USD 574.78M
流动负债
USD 62.74M
债务
USD 39.33M
EBIT
USD 23.96M
EBITDA
USD 43.96M
员工
824
EPS每股收益
USD 0.54
股本和储备
USD 1.39B
销售毛利
USD 108.55M
债务利息支出
USD 2K
利息收入
USD 3.48M
贷款资金
USD 0
市值
USD 3.23B
净收入
USD 25.49M
营业费用
USD 126.36M
营业利润
USD 23.96M
普通股股本
USD 79.79M
PE价格收益
42.77
税前利润
USD 26.52M
销售收入
USD 150.32M
销售和管理费用
USD 55.71M
股票
USD 22.66M
贸易债权人
USD 8.02M
应收帐款人
USD 54.18M


税前利润 更改 日
Agenus USD 39.21M 49.82M 2026-03
Agilent USD 408M 44M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
Bruker USD 117M 95.1M 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Illumina USD 260M 103M 2026-06
Intrexon USD -60.48M 27.09M 2024-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Laboratory Of America USD 8.61B 121.8M 2026-06
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
Myriad Genetics USD 4.6M 3.4M 2025-12
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Siemens EUR 2.86B 89M 2026-03
Sonic Healthcare AUD 402.01M 53.16M 2025-06
Thermo Fisher Scientific USD 1.73B 389M 2026-03
Veracyte USD 26.52M 3.45M 2026-06
Waters USD 356M 444M 2026-06